» Articles » PMID: 30534981

Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction

Abstract

Background: Drug-resistant minority variants (DRMinVs) detected in patients who recently acquired human immunodeficiency virus type 1 (HIV-1) can be transmitted, generated de novo through virus replication, or technical errors. The first form is likely to persist and result in treatment failure, while the latter two could be stochastic and transient.

Methods: Ultradeep sequencing of plasma samples from 835 individuals with recent HIV-1 infection in the United Kingdom was performed to detect DRMinVs at a mutation frequency between 2% and 20%. Sequence alignments including >110 000 HIV-1 partial pol consensus sequences from the UK HIV Drug Resistance Database (UK-HDRD), linked to epidemiological and clinical data from the HIV and AIDS Reporting System, were used for transmission cluster analysis. Transmission clusters were identified using Cluster Picker with a clade support of >90% and maximum genetic distances of 4.5% or 1.5%, the latter to limit detection to likely direct transmission events.

Results: Drug-resistant majority variants (DRMajVs) were detected in 66 (7.9%) and DRMinVs in 84 (10.1%) of the recently infected individuals. High levels of clustering to sequences in UK-HDRD were observed for both DRMajV (n = 48; 72.7%) and DRMinV (n = 63; 75.0%) sequences. Of these, 43 (65.2%) with DRMajVs were in a transmission cluster with sequences that harbored the same DR mutation compared to only 3 (3.6%) sequences with DRMinVs (P < .00001, Fisher exact test). Evidence of likely direct transmission of DRMajVs was observed for 25/66 (37.9%), whereas none were observed for the DRMinVs (P < .00001).

Conclusions: Using a densely sampled HIV-infected population, we show no evidence of DRMinV transmission among recently infected individuals.

Citing Articles

Empirical comparison of analytical approaches for identifying molecular HIV-1 clusters.

Novitsky V, Steingrimsson J, Howison M, Gillani F, Li Y, Manne A Sci Rep. 2020; 10(1):18547.

PMID: 33122765 PMC: 7596705. DOI: 10.1038/s41598-020-75560-1.


Surveillance of HIV-1 transmitted integrase strand transfer inhibitor resistance in the UK.

Mbisa J, Ledesma J, Kirwan P, Bibby D, Manso C, Skingsley A J Antimicrob Chemother. 2020; 75(11):3311-3318.

PMID: 32728703 PMC: 7566560. DOI: 10.1093/jac/dkaa309.


Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.

Mbunkah H, Bertagnolio S, Hamers R, Hunt G, Inzaule S, Wit T J Infect Dis. 2019; 221(10):1584-1597.

PMID: 31809534 PMC: 7184901. DOI: 10.1093/infdis/jiz650.

References
1.
Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M . British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016; 17 Suppl 4:s2-s104. DOI: 10.1111/hiv.12426. View

2.
Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A . Persistence of HIV-1 transmitted drug resistance mutations. J Infect Dis. 2013; 208(9):1459-63. PMC: 3789571. DOI: 10.1093/infdis/jit345. View

3.
Sluis-Cremer N, Tachedjian G . Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. Virus Res. 2008; 134(1-2):147-56. PMC: 2745993. DOI: 10.1016/j.virusres.2008.01.002. View

4.
Metzner K, Scherrer A, Preiswerk B, Joos B, von Wyl V, Leemann C . Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. J Infect Dis. 2013; 208(7):1102-12. DOI: 10.1093/infdis/jit310. View

5.
Lipscomb J, Switzer W, Li J, Masciotra S, Owen S, Johnson J . HIV reverse-transcriptase drug resistance mutations during early infection reveal greater transmission diversity than in envelope sequences. J Infect Dis. 2014; 210(11):1827-37. DOI: 10.1093/infdis/jiu333. View